Passage Bio (PASG) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

—

Revenue (quarter)

—

Revenue growth (year over year)

—

Gross profit (trailing twelve months)

—

Gross margin

—

Net income (trailing twelve months)

—

Net income (quarter)

−$7.8M

Net income growth (year over year)

+16.66%

Net margin

—

Return on equity

−169.09%

EPS (trailing twelve months)

−$11.32

Book value per share

$1.38

P/E (trailing twelve months)

—

Price to book

3.29

Debt to assets

82.30%

Payout ratio

—

Dividend yield

—

Company profile

Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.

• How do I buy stock in Passage Bio (PASG)?

  PASG trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.